Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas
- 1 October 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 35 (10), 1549-1556
- https://doi.org/10.1097/pas.0b013e31822895e5
Abstract
The need for effective targeted therapies for renal cell carcinomas (RCCs) has fueled the interest for understanding molecular pathways involved in the oncogenesis of kidney tumors. Aiming to analyze the expression status and prognostic significance of mTOR and hypoxia-induced pathway members in patients with clear cell RCC (ccRCC), tissue microarrays were constructed from 135 primary and 41 metastatic ccRCCs. Immunoexpression levels were compared and correlated with clinicopathologic parameters and outcome. PTEN levels were significantly lower in primary and metastatic ccRCCs compared with benign tissues (PP≤0.001). For phos-S6 and 4EBP1, levels were higher in primary ccRCC compared with benign tissues (PPPPP≤0.036), p27 levels with Fuhrman grade (P=0.031), and 4EBP1, p27, and HIF-1α levels with tumor size (P≤0.025). Tumor size, HIF-1α, and phos-S6 levels were associated with disease-specific survival (DSS) (P≤0.032) and tumor progression (P≤0.043). In conclusion, both mTOR and hypoxia-induced pathways were activated in primary and metastatic ccRCC. PTEN loss seems to be an early event during tumorigenesis. Tumor size, HIF-1α, and phos-S6 expression were found to be independent predictors of both DSS and tumor progression in primary ccRCC.This publication has 50 references indexed in Scilit:
- Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell CarcinomaPharmacoEconomics, 2010
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell CarcinomaThe Oncologist, 2010
- Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinomaBritish Journal of Cancer, 2009
- Hypoxia inducible factor-1α correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinomaJournal of Experimental & Clinical Cancer Research, 2009
- A complex interplay between Akt, TSC2 and the two mTOR complexesBiochemical Society Transactions, 2009
- A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer BiomarkersJournal of Clinical Oncology, 2008
- Genetics and epigenetics of renal cell cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2008
- Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell CarcinomaClinical Cancer Research, 2007
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinomaCancer Letters, 1997